|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
|
US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5705483A
(en)
*
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
|
CA2262647C
(en)
*
|
1996-08-08 |
2007-12-04 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
PT1629849E
(pt)
*
|
1997-01-07 |
2013-07-09 |
Amylin Pharmaceuticals Llc |
Composições farmacêuticas que compreendem exendinas e seus agonistas
|
|
WO1998043658A1
(en)
*
|
1997-03-31 |
1998-10-08 |
Eli Lilly And Company |
Glucagon-like peptide-1 analogs
|
|
US5981488A
(en)
*
|
1997-03-31 |
1999-11-09 |
Eli Lillly And Company |
Glucagon-like peptide-1 analogs
|
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US7220721B1
(en)
*
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
WO1999025727A2
(en)
|
1997-11-14 |
1999-05-27 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
WO1999029336A1
(en)
|
1997-12-05 |
1999-06-17 |
Eli Lilly And Company |
Glp-1 formulations
|
|
US6380357B2
(en)
|
1997-12-16 |
2002-04-30 |
Eli Lilly And Company |
Glucagon-like peptide-1 crystals
|
|
FR2777283B1
(fr)
*
|
1998-04-10 |
2000-11-24 |
Adir |
Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
DE19823831A1
(de)
*
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
|
DE19828113A1
(de)
*
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
|
EP1100530B1
(en)
*
|
1998-07-31 |
2003-10-08 |
Novo Nordisk A/S |
In-vitro stimulation of beta cell proliferation
|
|
EP1666054A1
(en)
|
1998-08-28 |
2006-06-07 |
Eli Lilly & Company |
Method for administering insulinotropic peptides
|
|
US6720407B1
(en)
*
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
|
AU765584B2
(en)
|
1998-09-17 |
2003-09-25 |
Eli Lilly And Company |
Protein formulations
|
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
|
US6284725B1
(en)
*
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
US7259136B2
(en)
*
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
KR20050037004A
(ko)
*
|
1998-12-07 |
2005-04-20 |
소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. |
Ｇｌｐ-1의 유사체
|
|
PL208751B1
(pl)
*
|
1998-12-07 |
2011-06-30 |
Sod Conseils Rech Applic |
Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
|
|
ES2249933T3
(es)
*
|
1998-12-22 |
2006-04-01 |
Eli Lilly And Company |
Formulacion autoestable de peptido 1 tipo glucagon.
|
|
EP1600162A1
(en)
*
|
1998-12-22 |
2005-11-30 |
Eli Lilly & Company |
Shelf-stable formulation of glucagon-like peptide-1
|
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
|
US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
|
WO2000069911A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
|
WO2000078333A2
(en)
*
|
1999-06-21 |
2000-12-28 |
Eli Lilly And Company |
Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
|
|
US6864234B1
(en)
*
|
1999-06-25 |
2005-03-08 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Somatostatin agonists
|
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
|
DK2280020T3
(en)
|
1999-06-29 |
2016-05-02 |
Mannkind Corp |
Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
|
|
DE19940130A1
(de)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
|
EP1741447B1
(en)
|
2000-01-21 |
2013-09-18 |
Novartis AG |
Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
|
|
US6448045B1
(en)
|
2000-03-10 |
2002-09-10 |
The Regents Of The University Of California |
Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
|
|
CA2400226C
(en)
*
|
2000-03-31 |
2007-01-02 |
Probiodrug Ag |
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
|
EP1803730A1
(en)
|
2000-04-12 |
2007-07-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
CN100469791C
(zh)
*
|
2000-06-16 |
2009-03-18 |
伊莱利利公司 |
胰高血糖素样肽-1类似物
|
|
KR100407792B1
(ko)
*
|
2000-08-02 |
2003-12-01 |
한국생명공학연구원 |
인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법
|
|
PE20020617A1
(es)
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
|
|
WO2002028181A1
(en)
*
|
2000-10-02 |
2002-04-11 |
Usv Limited |
Sustained release pharmaceutical compositions containing metformin and method of its production
|
|
ZA200302590B
(en)
*
|
2000-10-27 |
2004-04-02 |
Probiodrug Ag |
Method for the treatment of neurological and neuropsychological disorders.
|
|
EP1346722B1
(en)
|
2000-12-01 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Method for producing preparation containing bioactive substance
|
|
WO2002048192A2
(en)
*
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
|
WO2002047716A2
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
US20040143015A1
(en)
*
|
2001-03-12 |
2004-07-22 |
Villhauer Edwin Bernard |
Combination of organic compounds
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
US20030130199A1
(en)
*
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
|
US7368421B2
(en)
*
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
|
JP5562510B2
(ja)
*
|
2001-06-28 |
2014-07-30 |
ノヴォ ノルディスク アー／エス |
修飾ｇｌｐ−１の安定な処方剤
|
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
|
JP2005504766A
(ja)
*
|
2001-08-16 |
2005-02-17 |
プロバイオドラッグ アーゲー |
プロリンエンドペプチダーゼ阻害剤の、細胞内シグナルカスケード依存性イノシトール（１，４，５）トリホスフェート濃度調節への使用。
|
|
JP2005508895A
(ja)
*
|
2001-08-28 |
2005-04-07 |
イーライ・リリー・アンド・カンパニー |
Ｇｌｐ−１および基礎インスリンの予備混合物
|
|
US6844316B2
(en)
*
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
|
US6911324B2
(en)
|
2001-10-18 |
2005-06-28 |
The Regents Of The University Of California |
Induction of beta cell differentiation in human cells
|
|
US7179788B2
(en)
*
|
2001-10-19 |
2007-02-20 |
Eli Lilly And Company |
Biphasic mixtures of GLP-1 and insulin
|
|
US7332819B2
(en)
*
|
2002-01-09 |
2008-02-19 |
Micron Technology, Inc. |
Stacked die in die BGA package
|
|
EP2277910A1
(en)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP1463752A4
(en)
*
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
|
US7105489B2
(en)
*
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
RU2332229C2
(ru)
*
|
2002-02-20 |
2008-08-27 |
Эмисфире Текнолоджис Инк. |
Способ введения молекул glp-1
|
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
PT1494732E
(pt)
|
2002-03-20 |
2008-03-20 |
Mannkind Corp |
Aparelho de inalação
|
|
US20030232761A1
(en)
*
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
DK1525219T3
(da)
|
2002-07-04 |
2009-09-07 |
Zealand Pharma As |
GLP-1 og fremgangsm der til behandling af diabetes
|
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
WO2004031374A2
(en)
*
|
2002-09-18 |
2004-04-15 |
Prosidion Ltd. |
Secondary binding site of dipeptidyl peptidase iv (dp iv)
|
|
US20040058876A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Torsten Hoffmann |
Secondary binding site of dipeptidyl peptidase IV (DP IV)
|
|
AU2003271452A1
(en)
|
2002-09-25 |
2004-04-19 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
|
AU2003268621B2
(en)
|
2002-10-02 |
2009-01-15 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
|
US20040209801A1
(en)
*
|
2002-10-22 |
2004-10-21 |
Brand Stephen J. |
Treatment of diabetes
|
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
RU2234703C1
(ru)
*
|
2002-12-18 |
2004-08-20 |
Мищенко Борис Петрович |
Способ количественного определения гликогемоглобина
|
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
JP2006514990A
(ja)
*
|
2002-12-27 |
2006-05-18 |
ディオベックス， インコーポレイテッド |
インスリン誘発性低血糖の予防および制御のための組成物および方法
|
|
EP1594530A4
(en)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
|
DE602004025205D1
(de)
*
|
2003-02-19 |
2010-03-11 |
Ipsen Pharma |
Glp-1-analoga
|
|
HRP20050683A2
(en)
*
|
2003-03-19 |
2006-07-31 |
Eli Lilly And Company |
Polyethylene glycol linked glp-1 compounds
|
|
DK1633440T3
(da)
*
|
2003-04-15 |
2008-09-08 |
Opperbas Holding Bv |
Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler
|
|
KR20110059664A
(ko)
*
|
2003-05-05 |
2011-06-02 |
프로비오드룩 아게 |
글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
|
|
WO2004098591A2
(en)
*
|
2003-05-05 |
2004-11-18 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
|
|
WO2005000222A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Amylin Pharmaceuticals, Inc. |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
ATE529126T1
(de)
*
|
2003-06-03 |
2011-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische peptid zusammensetzungen
|
|
ATE541582T1
(de)
*
|
2003-06-03 |
2012-02-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
|
|
JP2007524592A
(ja)
*
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー／エス |
安定化された薬学的ペプチド組成物
|
|
EP2289498A1
(en)
*
|
2003-10-15 |
2011-03-02 |
Probiodrug AG |
Use of inhibitors of glutaminyl clyclase
|
|
CN1882356B
(zh)
*
|
2003-11-20 |
2015-02-25 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
|
ES2393335T3
(es)
|
2003-12-16 |
2012-12-20 |
Ipsen Pharma |
Análogos de GLP-1
|
|
WO2005058252A2
(en)
*
|
2003-12-16 |
2005-06-30 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Glp-1 pharmaceutical compositions
|
|
US20060286129A1
(en)
*
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
RU2006131046A
(ru)
*
|
2004-01-30 |
2008-03-10 |
Уэрейта Фармасьютикалз, Инк. (Ca) |
Совместное применение агониста glp-1 и соединений гастрина
|
|
EP1713780B1
(en)
|
2004-02-05 |
2012-01-18 |
Probiodrug AG |
Novel inhibitors of glutaminyl cyclase
|
|
HUE027902T2
(en)
*
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
|
WO2005103087A1
(en)
|
2004-04-23 |
2005-11-03 |
Conjuchem Biotechnologies Inc. |
Method for the purification of albumin conjugates
|
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
MX2007001903A
(es)
|
2004-08-20 |
2007-08-02 |
Mannkind Corp |
Catalisis de sintesis de dicetopiperazina.
|
|
KR20130066695A
(ko)
|
2004-08-23 |
2013-06-20 |
맨카인드 코포레이션 |
약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
|
|
JP4965446B2
(ja)
*
|
2004-08-31 |
2012-07-04 |
ノヴォ ノルディスク アー／エス |
ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
|
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
BRPI0517341A
(pt)
*
|
2004-11-12 |
2008-10-07 |
Novo Nordisk As |
composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
|
|
WO2006069779A1
(en)
*
|
2004-12-30 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
Preparing of peptides with excellent solubility
|
|
WO2006069697A1
(en)
*
|
2004-12-30 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
Colorimetrically assessing peptide characteristics
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
BRPI0606992A2
(pt)
|
2005-02-11 |
2009-07-28 |
Amylin Pharmaceuticals Inc |
análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
|
|
WO2006097535A2
(en)
*
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
EP2605013A1
(en)
|
2005-06-07 |
2013-06-19 |
The Rockefeller University |
Stimulation of pancreatic beta-cell proliferation
|
|
EP1904525A4
(en)
*
|
2005-06-30 |
2009-10-21 |
Ipsen Pharma |
GLP-1 PHARMACEUTICAL COMPOSITIONS
|
|
US20070004616A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Roland Cherif-Cheikh |
GLP-1 pharmaceutical compositions
|
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
|
KR101486397B1
(ko)
|
2005-09-14 |
2015-01-28 |
맨카인드 코포레이션 |
활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
|
|
ES2397289T3
(es)
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
|
GB0522295D0
(en)
*
|
2005-11-01 |
2005-12-07 |
Activotec Spp Ltd |
Peptides and uses thereof
|
|
EP1943275B1
(en)
*
|
2005-11-01 |
2010-06-16 |
Activotec SPP Limited |
Insulinotropic compounds and uses thereof
|
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
ES2779992T3
(es)
|
2005-12-20 |
2020-08-21 |
Univ Duke |
Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
EP1976876A4
(en)
*
|
2005-12-22 |
2010-01-13 |
Conjuchem Biotechnologies Inc |
PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
|
|
BRPI0707991B8
(pt)
|
2006-02-22 |
2021-05-25 |
Mannkind Corp |
métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
|
|
WO2007124461A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
|
AU2007263043B2
(en)
*
|
2006-06-23 |
2012-11-29 |
F. Hoffmann-La Roche Ag |
Insulinotropic peptide synthesis
|
|
JP2010500868A
(ja)
|
2006-07-18 |
2010-01-14 |
セントカー・インコーポレーテツド |
ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
TW200843794A
(en)
*
|
2006-12-21 |
2008-11-16 |
Centocor Inc |
Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
|
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
|
GB2448895A
(en)
*
|
2007-05-01 |
2008-11-05 |
Activotec Spp Ltd |
GLP-1 like compounds and uses thereof
|
|
CN101868476B
(zh)
|
2007-09-05 |
2015-02-25 |
诺沃-诺迪斯克有限公司 |
胰高血糖素样肽-1衍生物及其制药用途
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
KR101736502B1
(ko)
*
|
2007-10-24 |
2017-05-16 |
맨카인드 코포레이션 |
Ｇｌｐ-1에 의한 유해 효과의 예방 방법
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
JP5813323B2
(ja)
|
2007-10-24 |
2015-11-17 |
マンカインド コーポレイション |
活性薬剤の送達方法
|
|
JP5473925B2
(ja)
*
|
2007-10-27 |
2014-04-16 |
コーデン ファーマ コロラド インコーポレイテッド |
固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
|
|
US20090181037A1
(en)
*
|
2007-11-02 |
2009-07-16 |
George Heavner |
Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
|
|
CN102026666B
(zh)
*
|
2007-12-11 |
2013-10-16 |
常山凯捷健生物药物研发（河北）有限公司 |
促胰岛素肽缀合物制剂
|
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
US9358352B2
(en)
|
2008-06-13 |
2016-06-07 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
|
RU2608439C2
(ru)
|
2008-06-13 |
2017-01-18 |
Маннкайнд Корпорейшн |
Ингалятор для сухого порошка и система для доставки лекарственных средств
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
EP2609954B1
(en)
|
2008-06-20 |
2021-12-29 |
MannKind Corporation |
An interactive apparatus for real-time profiling of inhalation efforts
|
|
CA2726894A1
(en)
|
2008-06-27 |
2009-12-30 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
|
TWI532497B
(zh)
|
2008-08-11 |
2016-05-11 |
曼凱公司 |
超快起作用胰島素之用途
|
|
CN103736082A
(zh)
|
2008-10-17 |
2014-04-23 |
赛诺菲-安万特德国有限公司 |
胰岛素和glp-1激动剂的组合
|
|
JP5514831B2
(ja)
*
|
2008-11-17 |
2014-06-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病の治療のための置換二環式アミン
|
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
|
EP2676695A3
(en)
|
2009-03-11 |
2017-03-01 |
MannKind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
|
EP2430018B1
(en)
|
2009-05-15 |
2013-07-03 |
Novartis AG |
Benzoxazolone derivatives as aldosterone symthase inhibitors
|
|
SI2429995T1
(sl)
|
2009-05-15 |
2014-05-30 |
Novartis Ag |
Arilpiridini kot inhibitorji aldosteron sintaze
|
|
JP5420761B2
(ja)
|
2009-05-28 |
2014-02-19 |
ノバルティス アーゲー |
ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
|
|
MX2011012627A
(es)
|
2009-05-28 |
2011-12-14 |
Novartis Ag |
Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
|
|
CN102647979B
(zh)
|
2009-06-12 |
2015-03-04 |
曼金德公司 |
具有确定比表面积的二酮哌嗪颗粒
|
|
CA2804755C
(en)
|
2009-08-14 |
2018-06-05 |
Phasebio Pharmaceuticals, Inc. |
Modified vasoactive intestinal peptides
|
|
EP2496295A1
(en)
|
2009-11-03 |
2012-09-12 |
MannKind Corporation |
An apparatus and method for simulating inhalation efforts
|
|
CN102711804B
(zh)
|
2009-11-13 |
2015-09-16 |
赛诺菲-安万特德国有限公司 |
包含glp-1激动剂和甲硫氨酸的药物组合物
|
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
|
ES2551002T3
(es)
|
2009-11-17 |
2015-11-13 |
Novartis Ag |
Derivados de aril-piridina como inhibidores de la aldosterona sintasa
|
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
|
ES2472446T3
(es)
|
2009-11-30 |
2014-07-01 |
Novartis Ag |
Derivados de imidazol como inhibidores de aldosterona sintasa
|
|
US9168288B2
(en)
|
2010-04-09 |
2015-10-27 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
|
|
CN103003300B
(zh)
|
2010-04-27 |
2017-06-09 |
西兰制药公司 |
Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
|
|
JP5819946B2
(ja)
|
2010-05-17 |
2015-11-24 |
ベータ ファーマシューティカルズ カンパニー リミテッド |
新規のグルカゴン様ペプチド類似体、組成物、および使用方法
|
|
PT2611458T
(pt)
|
2010-08-30 |
2016-12-16 |
Sanofi Aventis Deutschland |
Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
|
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
|
RS60321B1
(sr)
|
2010-12-16 |
2020-07-31 |
Novo Nordisk As |
Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
|
|
WO2012098188A1
(en)
*
|
2011-01-19 |
2012-07-26 |
Novo Nordisk A/S |
Glp-1 particles and compositions
|
|
EP2694402B1
(en)
|
2011-04-01 |
2017-03-22 |
MannKind Corporation |
Blister package for pharmaceutical cartridges
|
|
RU2602601C2
(ru)
|
2011-04-12 |
2016-11-20 |
Ново Нордиск А/С |
Дважды ацилированные производные glp-1
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
EP2717902B1
(en)
|
2011-06-06 |
2018-01-24 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
|
ES2550357T3
(es)
|
2011-08-29 |
2015-11-06 |
Sanofi-Aventis Deutschland Gmbh |
Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
|
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
|
WO2013063160A1
(en)
|
2011-10-24 |
2013-05-02 |
Mannkind Corporation |
Methods and compositions for treating pain
|
|
BR112014010780A2
(pt)
|
2011-11-03 |
2017-04-25 |
Zealand Pharma As |
conjugados do peptídeo agonista do receptor glp-1-gastrina
|
|
CN110041399B
(zh)
|
2011-12-29 |
2023-12-12 |
诺沃—诺迪斯克有限公司 |
包含非成蛋白质性的氨基酸的二肽
|
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
|
LT2827885T
(lt)
|
2012-03-22 |
2018-10-10 |
Novo Nordisk A/S |
Glp-1 peptidų kompozicijos ir jų gavimas
|
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
|
EP2873422A4
(en)
|
2012-07-10 |
2015-12-30 |
Takeda Pharmaceutical |
PHARMACEUTICAL PREPARATION FOR INJECTION
|
|
CA2878457C
(en)
|
2012-07-12 |
2021-01-19 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
WO2014066856A1
(en)
|
2012-10-26 |
2014-05-01 |
Mannkind Corporation |
Inhalable influenza vaccine compositions and methods
|
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
|
|
PE20151666A1
(es)
|
2013-02-14 |
2015-11-19 |
Novartis Ag |
Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
|
|
EP3587404B1
(en)
|
2013-03-15 |
2022-07-13 |
MannKind Corporation |
Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
|
|
RU2671406C2
(ru)
|
2013-05-02 |
2018-10-31 |
Ново Нордиск А/С |
Пероральная дозированная форма соединений глюкагоноподобного пептида-1
|
|
CA2918369C
(en)
|
2013-07-18 |
2021-06-29 |
Mannkind Corporation |
Heat-stable dry powder pharmaceutical compositions and methods
|
|
TW201536814A
(zh)
|
2013-07-25 |
2015-10-01 |
Novartis Ag |
用於治療心臟衰竭之合成環狀多肽
|
|
PE20160991A1
(es)
|
2013-07-25 |
2016-10-15 |
Novartis Ag |
Bioconjugados de polipeptidos de apelina sintetica
|
|
EP3030294B1
(en)
|
2013-08-05 |
2020-10-07 |
MannKind Corporation |
Insufflation apparatus
|
|
PT3057984T
(pt)
|
2013-10-17 |
2018-10-24 |
Boehringer Ingelheim Int |
Análogos de glucagon acilados
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
|
JP2017503474A
(ja)
|
2013-11-06 |
2017-02-02 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
|
|
RU2016132342A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
|
|
JP6735674B2
(ja)
|
2014-01-09 |
2020-08-05 |
サノフイＳａｎｏｆｉ |
インスリンアスパルトの安定化された医薬製剤
|
|
KR20160104726A
(ko)
|
2014-01-09 |
2016-09-05 |
사노피 |
인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
|
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
|
WO2015172046A1
(en)
|
2014-05-08 |
2015-11-12 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
|
US10253078B2
(en)
|
2014-10-29 |
2019-04-09 |
Zealand Pharma A/S |
GIP agonist compounds and methods
|
|
KR102578030B1
(ko)
|
2014-12-12 |
2023-09-14 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린 글라진／릭시세나티드 고정비 제형
|
|
CN105820233B
(zh)
*
|
2015-01-04 |
2021-06-15 |
甘李药业股份有限公司 |
一种胰岛素衍生物的制备方法
|
|
CA2972871A1
(en)
|
2015-01-23 |
2016-07-28 |
Novartis Ag |
Synthetic apelin fatty acid conjugates with improved half-life
|
|
AU2016219513B2
(en)
|
2015-02-09 |
2021-09-30 |
Immunoforge Co., Ltd. |
Methods and compositions for treating muscle disease and disorders
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
DK3283507T3
(da)
|
2015-04-16 |
2020-01-02 |
Zealand Pharma As |
Acyleret glucagonanalog
|
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
|
EP4424320A3
(en)
|
2016-12-09 |
2025-06-11 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
EP4360651A3
(en)
|
2017-08-24 |
2024-07-17 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
|
HUE063787T2
(hu)
|
2018-02-02 |
2024-01-28 |
Novo Nordisk As |
Egy GLP-1 agonistát, egy N-(8-(2-hidroxibenzoil)amino) kaprilsav sót és egy síkosítóanyagot tartalmazó szilárd készítmények
|
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
|
CN113166204B
(zh)
|
2018-11-27 |
2025-01-28 |
诺华股份有限公司 |
作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
|
|
EP3887363A1
(en)
|
2018-11-27 |
2021-10-06 |
Novartis AG |
Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
|
|
GB201917723D0
(en)
*
|
2019-12-04 |
2020-01-15 |
Nv Rose Llc |
Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
|
|
TWI878456B
(zh)
|
2020-02-18 |
2025-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
|
WO2023084449A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
|
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|
|
WO2024123812A1
(en)
|
2022-12-05 |
2024-06-13 |
Shattuck Labs, Inc. |
Fusion proteins for the treatment of cardiometabolic diseases
|
|
WO2024241229A1
(en)
|
2023-05-24 |
2024-11-28 |
Novartis Ag |
Naphthyridinone derivatives for the treatment of a disease or disorder
|